Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received European Commission approval for an ...

The company’s product pipeline and regulatory situation make it primed for growth. Halozyme’s fourth-quarter fiscal 2024 earnings report showed that it passed $1 billion in annual revenue for ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo regimen of Darzalex, the antibody therapy of Johnson & Johnson (NYSE:JNJ ...

Halozyme Therapeutics (HALO) announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency ...

Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $66.00. The stock has a market cap of $7.33 billion, a price-to-earnings ratio of 17.30, a PEG ratio of 0.42 and a ...

It’s not HBO, it’s Max — but the new standalone logo for Warner Bros. Discovery‘s streamer now certainly looks like HBO’s at a glance. The Max streaming service has quietly launched a ...

Halozyme Therapeutics (NASDAQ:HALO) announced Monday that the European Commission has approved an injectable version of Johnson & Johnson’s (NYSE:JNJ) antitumor agent Rybrevant for certain ...

Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million.

(RTTNews) - Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission approval for an indication extension of DARZALEX ...

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor ...